http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Phase 3b Study Shows Significantly Less Bleeding with XARELTO® (rivaroxaban) Compared to Warfarin in People with Non-Valvular Atrial Fibrillation Following Percutaneous Coronary Intervention with Ste
-
New Phase 3 Data Show SIMPONI ARIA® (golimumab) Significantly Improved Signs and Symptoms in Patients with Active Ankylosing Spondylitis
-
Two Studies Reveal Differences In Real-World Treatment Patterns In Rheumatoid Arthritis Patients Taking REMICADE® (infliximab) Compared To CT-P13 (infliximab biosimilar)
-
Amgen (AMGN) Enters Multiple Myeloma Collaboration with Janssen
-
Janssen Announces Clinical Trial Collaboration and Supply Agreement with Amgen to Evaluate daratumumab (DARZALEX®) in Combination with carfilzomib (KYPROLIS®)
-
ASH 2016: Janssen to Present 43 Abstracts with Data on Ibrutinib, Daratumumab and Other Compounds Showing Treatment Advances in Malignant and Non-Malignant Hematologic Conditions
-
Janssen to Present Data Across Broad Rheumatology Portfolio and Immunology Pipeline at the 2016 American College of Rheumatology Meeting
-
Janssen Partners with University of Pennsylvania and Castleman Disease Collaborative Network to Launch First Global Patient Registry for Castleman Disease
-
EVARREST® Fibrin Sealant Patch Gains FDA Approval on Expanded Indication for General Hemostasis
-
Two New Real-World Studies Confirm Positive Efficacy and Safety Profile of XARELTO® (rivaroxaban) in Treating and Preventing Blood Clots
-
Ethicon Launches HARMONIC® HD 1000i Shears to address challenges in complex surgical procedures
-
BabyCenter Cost of Raising a Child Report Explores What the American Dream Means Today
-
Janssen Announces Significant Data from First Phase 3 of Guselkumab in Plaque Psoriasis (JNJ)
-
New Phase 3 Data Show Significant Efficacy Versus Placebo And Superiority Of Guselkumab Versus Humira® In Treatment Of Moderate To Severe Plaque Psoriasis
-
Janssen-Cilag Will Present Oncology Data at ESMO 2016
-
Janssen to present growing set of oncology data at the 2016 European Society for Medical Oncology (ESMO) Congress
-
FDA Approves STELARA® (ustekinumab) For Treatment Of Adults With Moderately To Severely Active Crohn's Disease
-
Janssen Announces FDA Approval of STELARA as Crohn's Disease Treatment
-
FDA Approves STELARA® (ustekinumab) For Treatment Of Adults With Moderately To Severely Active Crohn's Disease
-
Janssen Announces Submission of Sirukumab BLA to FDA as RA Treatment
-
Janssen Submits Application Seeking Approval of Sirukumab in United States for Rheumatoid Arthritis
-
Johnson & Johnson Advances Commitment to Improve Global Health and Well-Being
-
Abbott (ABT) to Sell Abbott Medical Optics to Johnson & Johnson (JNJ) in $4.33B Deal
-
Janssen Receives Positive CHMP Opinion on STELARA as Crohn’s Disease Treatment (JNJ)
-
Janssen Receives CHMP Positive Opinion for STELARA® (ustekinumab) Recommending Approval for the Treatment of Moderately to Severely Active Crohn’s Disease in the European Union
-
Janssen Announces Submission of Marketing App in Europe for Darunavir-Based Single Tablet Regimen (JNJ)
-
Janssen Submits Marketing Authorisation Application for Darunavir-Based Single Tablet Regimen for Treatment of HIV-1 to European Medicines Agency
-
Janssen to Make Several INVOKANA Presentations at EASD Annual Meeting
-
Janssen to Present Data from Nine Abstracts on INVOKANA® (canagliflozin) at 2016 European Association for the Study of Diabetes Annual Meeting
-
Janssen to Present Data from Nine Abstracts on INVOKANA® (canagliflozin) at 2016 European Association for the Study of Diabetes Annual Meeting
-
BabyCenter Creates First Amazon Alexa Skill To Provide Pregnancy Resources For Expectant Parents
-
BabyCenter Creates First Amazon Alexa Skill To Provide Pregnancy Resources For Expectant Parents
-
BabyCenter Creates First Amazon Alexa Skill To Provide Pregnancy Resources For Expectant Parents
-
BabyCenter Creates First Amazon Alexa Skill To Provide Pregnancy Resources For Expectant Parents
-
Ethicon Announces Strategic Collaboration With Touch Surgery To Evolve Medical Education
-
Janssen-Cilag Announces Submission of Type 2 Variation App for DARZALEX in Europe (JNJ)
-
Janssen Submits Application to the European Medicines Agency (EMA) to Expand Use of DARZALEX®▼ (daratumumab) to Include Combination with Standard of Care Regimens
-
Janssen Announces 25 Presentations at ESC Congress (JNJ)
-
Janssen Announces 25 Presentations at Upcoming ESC Congress 2016, Including New Clinical and Real-World Research on XARELTO® and Latest Findings from REVISIT-US
-
Janssen Submits Application to U.S. FDA to Expand Indication for Daratumumab (DARZALEX®)
-
Janssen Research (JNJ) Reports Breakthrough Therapy Designation for Esketamine
-
Esketamine Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Major Depressive Disorder with Imminent Risk for Suicide
-
Bristol-Myers Squibb (BMY), Janssen Enter New Immuno-Oncology-Focused Research Collaboration
-
Janssen Announces Clinical Collaboration with Bristol-Myers Squibb to Evaluate Immuno-oncology Combination in Lung Cancer
-
Janssen Receives FDA Breakthrough Therapy Designation for DARZALEX in Multiple Myeloma (JNJ)
-
Daratumumab (DARZALEX®) Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Use in Combination with Standard of Care Regimens for Patients with Multiple Myeloma
-
BabyCenter Finds Politics And Patriotism Are Influencing Baby Names
-
Canagliflozin Phase 2 Study Demonstrates Glycemic Improvements in Adults With Type 1 Diabetes
-
Ethicon Study: Bariatric Surgery Found to Be a More Effective Way to Control Diabetes in Obese Asian Indian Patients
-
Experts Call For New Strategies to Address Diabetes in Obese Patients
